Join
Live feed
·
PRReleasevia Quantisnow
MaxCyte Inc. logo

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

ByQuantisnow·Wall Street's wire, on your screen.
MXCT· MaxCyte Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MXCT (MaxCyte Inc.) and more on Quantisnow.